UCB (OTCMKTS:UCBJY – Get Rating) is one of 371 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare UCB to related companies based on the strength of its dividends, valuation, analyst recommendations, earnings, institutional ownership, risk and profitability.
Institutional & Insider Ownership
25.2% of shares of all “Biotechnology” companies are held by institutional investors. 25.4% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Dividends
UCB pays an annual dividend of $0.36 per share and has a dividend yield of 0.8%. UCB pays out 46.6% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 2.7% and pay out 12,180.7% of their earnings in the form of a dividend.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| UCB | 0 | 0 | 2 | 0 | 3.00 |
| UCB Competitors | 596 | 1546 | 4164 | 41 | 2.58 |
UCB currently has a consensus price target of $96.50, indicating a potential upside of 111.48%. As a group, “Biotechnology” companies have a potential upside of 106.60%. Given UCB’s stronger consensus rating and higher probable upside, equities research analysts plainly believe UCB is more favorable than its peers.
Profitability
This table compares UCB and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| UCB | N/A | N/A | N/A |
| UCB Competitors | -918.43% | -61.30% | -19.52% |
Valuation & Earnings
This table compares UCB and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| UCB | N/A | N/A | 59.77 |
| UCB Competitors | $118.97 million | -$2.93 million | 18.01 |
UCB’s peers have higher revenue, but lower earnings than UCB. UCB is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
UCB beats its peers on 8 of the 13 factors compared.
About UCB
UCB SA engages in the research and development biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
